Related Experiment Video
Updated: Feb 15, 2026
09:36
RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
Published on: April 10, 2018
26.4K
Long non-coding RNA PCAT-1 in human cancers: A meta-analysis.
Chaojie Liang1, Zining Qi1, Hua Ge2
1Department of General Surgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|January 30, 2018
Summary
Prostate cancer-associated transcript-1 (PCAT-1) is overexpressed in cancers and linked to poorer survival. High PCAT-1 expression correlates with advanced tumor stage and metastasis, suggesting its potential as a cancer biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer-associated non-coding RNA transcript-1 (PCAT-1) is a long non-coding RNA.
- PCAT-1 is increasingly recognized for its upregulation across various human malignancies.
Purpose of the Study:
- To evaluate the clinicopathological significance of PCAT-1 in malignant tumors.
- To assess the prognostic value of PCAT-1 expression in cancer patients.
Main Methods:
- A comprehensive meta-analysis was performed.
- Systematic literature searches were conducted across multiple databases (PubMed, Medline, Web of Science, EMBASE, etc.).
- Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated.
Main Results:
- The meta-analysis included 1005 patients from nine studies.
- High PCAT-1 expression was significantly associated with tumor depth, lymph node metastasis, distant metastasis, and TNM stage.
- Elevated PCAT-1 expression correlated with poorer overall survival (OS) and disease-free survival (DFS).
Conclusions:
- PCAT-1 expression is strongly linked to clinicopathological features like metastasis and tumor stage.
- PCAT-1 may serve as an independent predictive factor for overall survival in cancer patients.
- Further large-scale studies are recommended to validate PCAT-1 as a prognostic biomarker.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
02:39lncRNA - Long Non-coding RNAs
3.7K
3.7K
01:32RNA Splicing
60.7K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.7K
02:53Ribosomal RNA Synthesis
14.9K
Ribosome synthesis is a highly complex and coordinated process involving more than 200 assembly factors. The synthesis and processing of ribosomal components occurs not only in the nucleolus but also in the nucleoplasm and the cytoplasm of eukaryotic cells.
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
14.9K
01:29Nursing Code of Ethics
4.8K
The Nursing Code of Ethics sets the ethical benchmark for the profession, and guides nurses in ethical analysis and decision making at the societal, organizational, and clinical levels. The code encompasses showing compassion and respect for the patient, their families, and communities in all circumstances while committing to providing patient-centered care. In addition, the code states that nurses must advocate for the patient by defending a cause or recommendation to protect their rights,...
4.8K
01:21Cancer Survival Analysis
776
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
776